-

PerkinElmer Launches BioQule NGS System to Automate Library Preparation

Affordable, easy-to-use benchtop system empowers labs of all sizes to both generate and quality control NGS libraries for genomic analysis

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced the launch of the research use only (RUO) BioQule™ NGS System – an automated benchtop solution for next-generation sequencing (NGS) library preparation of up to eight samples. By incorporating automated thermocycling, integrated quality control through optical quantification and robust liquid handling technology into a single device, the BioQule NGS System enables researchers to produce high quality NGS libraries that yield reliable, reproducible results in a variety of applications requiring genomic analysis.

Unlike existing solutions for NGS library preparation, which are expensive and rely on external solutions to perform concentration measurements on their libraries, the BioQule NGS System provides in-built quantification of NGS libraries it creates. Methods and kits used with the BioQule NGS System are predeveloped and pre-verified, and the entire system can be installed, set-up and run by the user without any specialized vendor support.

“Library preparation for NGS is a critical, yet complex and often error-prone process that can be optimized with automation, both in terms of yield and cost benefits,” said PerkinElmer SVP of Diagnostics Yves Dubaquie. “The BioQule NGS System is an ideal solution for any lab performing NGS library preparation, including small and mid-sized labs pursuing research in genomics and transcriptomics, or large reference laboratories. The BioQule NGS System can be customized to a given lab’s workflow requirements and requires no prior automation experience to use.”

In addition to its simple design and walk-away automation capabilities, the BioQule NGS System expands opportunities in NGS library preparation by requiring as little as 10 ng of starting material to create libraries, while others require 50 ng or more. PerkinElmer currently offers two DNA library prep kits that are automated on the system – the NEXTFLEX® Rapid XP DNA-Seq Kit and the NEXTFLEX® Rapid DNA-Seq Kit 2.0. Additional library prep kits compatible with BioQule NGS System are currently in development.

The BioQule NGS System will be on display at PerkinElmer’s booth (located in the Fulton suite) at the Advances in Genome Biology and Technology (AGBT) General Meeting from June 6-9, 2022 in Orlando, Florida.

To learn more about the BioQule NGS System and PerkinElmer’s end-to-end automated genomics workflows, visit this webpage.

About PerkinElmer

PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $5 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

Contacts

Investor Relations:
Stephen Willoughby
(781) 663-5677
stephen.willoughby@perkinelmer.com

Media Relations:
Chet Murray
(781) 663-5719
chet.murray@perkinelmer.com

PerkinElmer, Inc.

NYSE:RVTY
Details
Headquarters: Waltham, Massachusetts
CEO: Prahlad Singh
Employees: 11,000
Organization: PUB

Release Versions

Contacts

Investor Relations:
Stephen Willoughby
(781) 663-5677
stephen.willoughby@perkinelmer.com

Media Relations:
Chet Murray
(781) 663-5719
chet.murray@perkinelmer.com

More News From PerkinElmer, Inc.

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for t...

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from disco...

Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 2026. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Inves...
Back to Newsroom